Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 250
Single User License Price INR 17798
Corporate User License Price USD 750
Corporate User License Price INR 53393
Site License Price USD 500
Site License Price INR 35595
Request a Quote

Report Title

AveXis Inc (AVXS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Quote Request for License Type
License Type Price  
Single User License USD 250
Site License USD 500
Enterprise Wide License USD 750
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

AveXis Inc (AVXS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


Quote Request for License Type
License Type Price  
Single User License USD 250
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

AveXis Inc (AVXS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

AveXis Inc (AVXS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile



Executive Summary

Summary

AveXis Inc (AveXis), formerly BioLife Cell Bank Inc, is a biotechnology company that develops innovative treatments for rare and potentially fatal neurological genetic diseases. The company offers AVXS-101, a proprietary gene therapy candidate in phase 1 targeted at the treatment of spinal muscular atrophy. Its AVXS-101 received orphan drug designation for the treatment of all types of SMA from the US FDA; fast track designation for the treatment of SMA Type 1; and breakthrough therapy designation for the treatment of SMA Type 1 in pediatric patients. It works in collaboration with various academic institutes and research centers to advance its investigational product candidates. AveXis is headquartered in Bannockburn, Illinois, the US.

AveXis Inc (AVXS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

AveXis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

AveXis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

AveXis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

AveXis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

AveXis Inc, Medical Devices Deals, 2012 to YTD 2018 10

AveXis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

AveXis Inc, Pharmaceuticals & Healthcare, Deal Details 13

Venture Financing 13

AveXis Raises USD65 Million in Venture Financing 13

AveXis Raises USD10 Million in Series C Financing Round 15

Partnerships 16

AveXis Enters into Licensing Agreement with Genethon and Centre National de la Recherche Scientifique 16

Licensing Agreements 17

AveXis Enters into Licensing Agreement with Regenxbio 17

AveXis Enters into Licensing Agreement with Nationwide Children's Hospital for Development of Rett syndrome 19

AveXis Enters into Licensing Agreement with Nationwide Children's Hospital for Development of Amyotrophic Lateral Sclerosis 20

Asklepios BioPharma Enters into Licensing Agreement with AveXis 21

AveXis Amends Licensing Agreement With ReGenX Biosciences 22

AveXis Amends Licensing Agreement with Nationwide Children's Hospital 23

Equity Offering 24

AveXis Raises USD460 Million in Public Offering of Shares 24

AveXis Raises USD287.8 Million in Public Offering of Shares 26

AveXis Raises USD146.6 Million in Public Offering of Shares 28

AveXis Completes Underwriter's Exercise of Over-Allotment Option of IPO 30

AveXis Raises USD2 Million in Private Placement of Shares and Warrants 31

Debt Offering 32

AveXis Raises USD0.5 Million in Private Placement of 8% Notes 32

Acquisition 33

Novartis Acquires AveXis for USD8.7 Billion 33

AveXis Inc-Key Competitors 35

AveXis Inc-Key Employees 36

AveXis Inc-Locations And Subsidiaries 37

Head Office 37

Other Locations & Subsidiaries 37

Recent Developments 38

Financial Announcements 38

May 03, 2018: AveXis Reports First Quarter 2018 Financial and Operating Results 38

Feb 27, 2018: AveXis Reports Fourth Quarter and Full Year 2017 Financial and Operating Results 40

Nov 09, 2017: AveXis Reports Third Quarter 2017 Financial and Operating Results 42

Aug 10, 2017: AveXis Reports Second Quarter 2017 Financial and Operating Results 44

May 11, 2017: AveXis Reports First Quarter 2017 Financial and Operating Results 46

Corporate Communications 48

Feb 15, 2017: AveXis Appoints Rick Modi as Senior Vice President and Chief Business Officer 48

Product Approvals 49

Mar 27, 2018: AveXis Gene Therapy Awarded SAKIGAKE Designation for Spinal Muscular Atrophy Type 1 49

Jan 04, 2018: AveXis Announces Alignment with FDA on Next Steps Toward a BLA Submission for AVXS-101 in SMA Type 1 50

Jun 14, 2017: AveXis Announces Alignment with FDA on GMP Commercial Manufacturing Process for AVXS-101 51

Jan 31, 2017: AveXis Gene Therapy AVXS-101 Granted Access into EMA PRIME Program for Spinal Muscular Atrophy Type 1 53

Clinical Trials 54

May 08, 2018: AveXis Issues Community Statement on the SPR1NT Trial 54

Apr 25, 2018: AveXis Announces First Patient Dosed in Phase 3 Trial of AVXS-101 in Pre-Symptomatic SMA Types 1, 2 and 3 55

Apr 24, 2018: AveXis Presents Initial Data from Pivotal U.S. Trial for SMA Type 1 and 24-Month Follow-Up Data from Phase 1 Trial of AVXS-101 in SMA Type 1 at the Annual Meeting of the American Academy of Neurology 57

Apr 19, 2018: AveXis to Present AVXS-101 Data at the Annual Meeting of the American Academy of Neurology 59

Jan 30, 2018: AveXis to Initiate Screening for Remaining Patients in Pivotal Trial of AVXS-101 for SMA Type 1 Following Review of Preliminary Data from First Three Patients 60

Jan 16, 2018: AveXis Announces Expanded Clinical Development Program for AVXS-101 in Spinal Muscular Atrophy 61

Dec 13, 2017: AveXis Announces Plan to Initiate Phase 1 Trial in SMA Type 2 Utilizing Intrathecal Delivery of AVXS-101 62

Nov 01, 2017: AveXis Announces New England Journal of Medicine Publication of Phase 1 Data of AVXS-101 Gene Replacement Therapy in Spinal Muscular Atrophy Type 1 64

Oct 03, 2017: AveXis to Report Top-line Data from the Phase 1 Clinical Trial of AVXS-101 in SMA Type 1 at the International Annual Congress of the World Muscle Society 66

Sep 29, 2017: AveXis Announces Plan to Initiate Pivotal Trial of AVXS-101 in SMA Type 1 Using Product from New GMP Commercial Process 67

Apr 25, 2017: AveXis Presents Results from Phase 1 Trial of AVXS-101 in SMA Type 1 at the Annual Meeting of the American Academy of Neurology 69

Apr 18, 2017: AveXis to Host Webcast of Preclinical and Clinical Studies of AVXS-101 as Presented at the Annual Meeting of the American Academy of Neurology 71

Mar 16, 2017: AveXis Reports Topline Results from Phase 1 Trial of AVXS-101 in SMA Type 1 and Fourth Quarter and Full Year 2016 Financial and Operating Results 72

Mar 09, 2017: AveXis to Report Topline Phase 1 Trial Results in SMA Type 1 75

Mar 02, 2017: AveXis to Present Results from Phase 1 Trial of AVXS-101 in SMA Type 1 at AAN Annual Meeting 76

Feb 06, 2017: AveXis Announces Single-Arm Design for European Pivotal Study of AVXS-101 in SMA Type 1 Patients 77

Appendix 78

Methodology 78

About GlobalData 78

Contact Us 78

Disclaimer 78

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

AveXis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

AveXis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

AveXis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

AveXis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

AveXis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

AveXis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

AveXis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

AveXis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

AveXis Inc, Medical Devices Deals, 2012 to YTD 2018 10

List of Tables

AveXis Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

AveXis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

AveXis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

AveXis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

AveXis Inc, Deals By Therapy Area, 2012 to YTD 2018 9

AveXis Inc, Medical Devices Deals, 2012 to YTD 2018 10

AveXis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

AveXis Raises USD65 Million in Venture Financing 13

AveXis Raises USD10 Million in Series C Financing Round 15

AveXis Enters into Licensing Agreement with Genethon and Centre National de la Recherche Scientifique 16

AveXis Enters into Licensing Agreement with Regenxbio 17

AveXis Enters into Licensing Agreement with Nationwide Children's Hospital for Development of Rett syndrome 19

AveXis Enters into Licensing Agreement with Nationwide Children's Hospital for Development of Amyotrophic Lateral Sclerosis 20

Asklepios BioPharma Enters into Licensing Agreement with AveXis 21

AveXis Amends Licensing Agreement With ReGenX Biosciences 22

AveXis Amends Licensing Agreement with Nationwide Children's Hospital 23

AveXis Raises USD460 Million in Public Offering of Shares 24

AveXis Raises USD287.8 Million in Public Offering of Shares 26

AveXis Raises USD146.6 Million in Public Offering of Shares 28

AveXis Completes Underwriter's Exercise of Over-Allotment Option of IPO 30

AveXis Raises USD2 Million in Private Placement of Shares and Warrants 31

AveXis Raises USD0.5 Million in Private Placement of 8% Notes 32

Novartis Acquires AveXis for USD8.7 Billion 33

AveXis Inc, Key Competitors 35

AveXis Inc, Key Employees 36

AveXis Inc, Subsidiaries 37

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

AveXis Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person